Retatrutide and Liver Fat: The MASH Connection
Retatrutide
82.4% liver fat reduction
The highest retatrutide dose reduced liver fat by 82.4% at 24 weeks in adults with MASLD and obesity, with 86% achieving normal liver fat levels.
Sanyal et al., Nature Medicine, 2024
Sanyal et al., Nature Medicine, 2024
View as imageRetatrutide reduced liver fat by more than 80% in a 48-week clinical trial, a figure that surpasses every other incretin-based drug tested for fatty liver disease to date.[1] That result, published in Nature Medicine in 2024, positioned this triple agonist as a serious contender in a disease that affects roughly 38% of all adults worldwide and has, until recently, had almost no pharmacological treatment options.
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called NAFLD, describes excess fat accumulation in the liver driven by metabolic risk factors like obesity, insulin resistance, and dyslipidemia. Its more dangerous progression, metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), involves inflammation and can lead to fibrosis, cirrhosis, and liver failure. The 2023 Delphi consensus renamed these conditions to remove stigmatizing language and better reflect their metabolic origins.
What makes retatrutide's liver data so striking is not just the magnitude of fat reduction. It is the mechanism behind it. Unlike semaglutide (a single GLP-1 agonist) or tirzepatide (a dual GLP-1/GIP agonist), retatrutide adds glucagon receptor activation to the equation. That third receptor appears to be the key to its liver-specific effects, because glucagon directly stimulates hepatic fatty acid oxidation and suppresses lipogenesis in the liver.[2]
Key Takeaways
- Retatrutide 12 mg reduced liver fat by 82.4% at 24 weeks and achieved normal liver fat levels in 93% of participants at 48 weeks (Sanyal et al., 2024)
- The phase 2a MASLD substudy enrolled 98 participants with baseline liver fat of 10% or more, measured by MRI-PDFF (Sanyal et al., 2024)
- Glucagon receptor activation distinguishes retatrutide from semaglutide and tirzepatide by directly targeting hepatic fat metabolism (Ganamurali and Sabarathinam, 2026)
- Semaglutide achieved MASH resolution in 29.7% of patients at 72 weeks in a phase 3 biopsy trial (Sanyal et al., 2025), while tirzepatide achieved 62% MASH resolution at 52 weeks (Loomba et al., 2024)
- A meta-analysis of 878 patients across three retatrutide trials found significant reductions in body weight (14.33%), BMI, fasting glucose, HbA1c, and blood pressure (Abdrabou et al., 2025)
- Phase 3 TRIUMPH-4 results showed 28.7% weight loss at 68 weeks, with additional MASLD-specific trials underway
What Is MASLD and Why Current Treatments Fall Short
MASLD is defined by hepatic steatosis (5% or more liver fat content by imaging) in the presence of at least one cardiometabolic risk factor. It sits on a spectrum: simple steatosis can progress to MASH, which involves hepatocyte injury and inflammation, and from there to fibrosis and eventually cirrhosis.
The numbers are staggering. An estimated 38% of adults globally have MASLD, a prevalence that has risen steadily over three decades in parallel with obesity rates. Among people with type 2 diabetes, prevalence reaches 65%. MASH specifically affects an estimated 5-7% of the general population, though the true figure is likely higher because diagnosis often requires liver biopsy. Latin America has the highest regional prevalence at 44.4%, while Western Europe sits at 25.1%.
The disease burden extends beyond the liver. MASLD is associated with increased cardiovascular mortality, type 2 diabetes progression, chronic kidney disease, and hepatocellular carcinoma. Among patients with biopsy-confirmed MASLD, 41% already have significant fibrosis and 15.5% have advanced fibrosis. The healthcare costs are enormous: MASLD-related liver transplants are rising, and the disease is projected to affect more than 55% of adults by 2040 if current trends continue.
Until March 2024, there was no FDA-approved drug specifically for MASH. Resmetirom, a thyroid hormone receptor-beta agonist, became the first when it received accelerated approval for MASH with moderate to advanced fibrosis. Semaglutide later gained approval for related metabolic indications. But the treatment landscape remains thin relative to the disease burden, and neither drug directly targets the liver's fat metabolism pathways the way glucagon receptor activation does.
This is where how retatrutide targets three receptors at once becomes relevant to the liver fat conversation.
How Retatrutide's Triple Mechanism Targets the Liver
Retatrutide (LY3437943) is a single peptide that simultaneously activates three receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and the glucagon receptor (GCGR).[3]
Each receptor contributes differently to metabolic outcomes:
GLP-1 receptor activation reduces appetite, slows gastric emptying, and improves insulin secretion. This is the mechanism behind semaglutide's effects. GLP-1 agonism drives weight loss, and weight loss alone can reduce liver fat. But GLP-1 does not directly act on hepatic lipid metabolism in a major way.[4]
GIP receptor activation enhances insulin sensitivity and may improve lipid handling. Combined with GLP-1, this is the basis for tirzepatide's dual mechanism. The GIP component may contribute to more efficient fat distribution and adipose tissue function.[5]
Glucagon receptor activation is what sets retatrutide apart for liver disease. Glucagon acts directly on hepatocytes to stimulate fatty acid beta-oxidation, the process by which the liver burns stored fat for energy. It also reduces de novo lipogenesis, the liver's production of new fat from carbohydrates. In animal models, glucagon receptor signaling reversed hepatic steatosis independent of weight loss.[6] A 2025 preclinical comparison found that retatrutide was superior to both liraglutide and tirzepatide at reducing liver triglycerides in diabetic mice.[7]
This triple mechanism means retatrutide reduces liver fat through at least two independent pathways: indirectly through weight loss (GLP-1 and GIP) and directly through hepatic fat burning (glucagon). That dual attack may explain why the liver fat reductions seen in trials are larger than what weight loss alone would predict.
The balance of these three receptor activities is carefully engineered. Glucagon on its own raises blood glucose, which would be counterproductive in a population with high rates of insulin resistance and type 2 diabetes. But the GLP-1 and GIP components counteract glucagon's glycemic effects while preserving its liver-specific fat-burning action. In the Rosenstock et al. (2023) type 2 diabetes trial, retatrutide 12 mg reduced HbA1c by 2.02% at 24 weeks, demonstrating that glucose control is maintained despite glucagon receptor activation.[3]
For a deeper look at this mechanism, see our article on how retatrutide targets three receptors at once. Mazdutide, another drug in development, uses a similar glucagon-inclusive approach; we cover it in mazdutide: the GLP-1/glucagon agonist from China's pipeline.
The Phase 2a MASLD Trial: Breaking Down the Numbers
The landmark retatrutide liver fat study was a substudy of the larger phase 2 obesity trial, published by Sanyal et al. in Nature Medicine in 2024.[1] It enrolled 98 participants with MASLD, defined as 10% or more liver fat content measured by MRI-PDFF (proton density fat fraction), a validated imaging method.
Liver fat reduction at 24 weeks
Participants received once-weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks.
| Dose | Mean relative liver fat change (24 wk) | Normal liver fat achieved (24 wk) |
|---|---|---|
| Placebo | +0.3% | 0% |
| 1 mg | -42.9% | 27% |
| 4 mg | -57.0% | 52% |
| 8 mg | -81.4% | 79% |
| 12 mg | -82.4% | 86% |
All active doses achieved statistically significant reductions versus placebo (P < 0.001). The dose-response was steep between 1 mg and 8 mg, with a plateau between 8 mg and 12 mg, suggesting near-maximal liver fat clearance at the higher doses.
Resolution of steatosis at 48 weeks
At 48 weeks, the results were even more pronounced. Normal liver fat (below 5%) was achieved by 89% of participants in the 8 mg group and 93% in the 12 mg group.[1] The 86% relative liver fat reduction observed with retatrutide 12 mg at 48 weeks is among the largest treatment effects ever reported for any pharmacological intervention in MASLD.
Metabolic improvements alongside liver fat reduction
Liver fat reductions correlated strongly with reductions in body weight, visceral adipose tissue (VAT), and abdominal subcutaneous adipose tissue (ASAT). Fasting triglycerides decreased by more than 40% at the 8 mg and 12 mg doses after 48 weeks, and these reductions were statistically associated with reduced liver fat. Fasting insulin dropped by 37.3% to 70.9% across retatrutide doses, and HOMA2-IR (a measure of insulin resistance) decreased by 35.8% to 69.3%. Adiponectin, a hormone associated with metabolic health, increased by 29.8% to 99.3% across doses. A body composition substudy confirmed that retatrutide 8 mg reduced total body fat mass by 26.1% at 36 weeks.[8]
What this trial did not measure
The substudy used MRI-PDFF to measure liver fat content but did not include liver biopsies. This means it could not assess inflammation, hepatocyte ballooning, or fibrosis stage, the histological markers that define MASH and determine disease severity. It also excluded participants with type 2 diabetes and did not enrich for patients with established MASH or significant fibrosis. The sample was predominantly white and based entirely in the United States. At 48 weeks, MRI data was missing for 56.1% of participants, a substantial dropout that limits the long-term estimates.
How Retatrutide Compares to Other Liver Fat Treatments
Comparing across different trials requires caution because study populations, endpoints, and durations differ. That said, the magnitude of retatrutide's liver fat effects stands out.
Semaglutide (GLP-1 agonist)
The phase 3 ESSENCE trial, published by Sanyal et al. in the New England Journal of Medicine in 2025, tested semaglutide 2.4 mg weekly in 800 participants with biopsy-confirmed MASH and stage F2-F3 fibrosis.[9] MASH resolution without worsening of fibrosis occurred in 29.7% of the semaglutide group versus 13.2% on placebo at 72 weeks. Fibrosis improvement of at least one stage was observed in 32.8% versus 23.0% on placebo. Mean weight loss was approximately 10.5%.
Semaglutide's liver effects appear to be driven primarily by weight loss and systemic metabolic improvement rather than direct hepatic action. The MASH resolution rates are meaningful but modest compared to retatrutide's liver fat clearance by imaging.
Tirzepatide (GLP-1/GIP dual agonist)
The SYNERGY-NASH trial, published by Loomba et al. in the NEJM in 2024, tested tirzepatide in 190 participants with biopsy-confirmed MASH and stage F2-F3 fibrosis.[10] MASH resolution without worsening fibrosis was achieved in 62% of the 15 mg group versus 10% on placebo at 52 weeks. Fibrosis improvement of at least one stage occurred in 51% of the 15 mg group versus 30% on placebo.
Tirzepatide's dual mechanism provides greater liver benefit than GLP-1 alone, but it lacks the direct hepatic fat-burning effect of glucagon receptor activation.
Survodutide (GLP-1/glucagon dual agonist)
Survodutide provides an informative comparison because, like retatrutide, it includes glucagon receptor agonism. In a phase 2 NEJM trial of 293 adults with biopsy-confirmed MASH, survodutide achieved MASH resolution in up to 62% of patients at 48 weeks at the 4.8 mg dose, versus 14% on placebo.[13] Liver fat decreased by at least 30% in 57-67% of participants. These results suggest that the glucagon component contributes meaningfully to hepatic outcomes, supporting the rationale for retatrutide's triple mechanism.
Resmetirom (thyroid hormone receptor-beta agonist)
Resmetirom, the first FDA-approved MASH drug, works through an entirely different pathway: activating thyroid hormone receptor-beta in the liver to increase lipid metabolism. It achieved MASH resolution in approximately 30% of patients and fibrosis improvement in about 24% in phase 3 trials. Its mechanism is complementary rather than competitive with incretin-based approaches.
Where retatrutide fits
Retatrutide's liver fat reduction by imaging (82.4% at 24 weeks) exceeds what any single-target or dual-target drug has achieved. However, the comparison is imperfect: the Sanyal trial measured fat content by MRI, not histological MASH resolution. Semaglutide and tirzepatide trials used liver biopsy to assess inflammation and fibrosis, endpoints that MRI-PDFF cannot capture.
The progression tells a clear story about mechanism: GLP-1 alone (semaglutide) reduces liver fat primarily through weight loss. Adding GIP (tirzepatide) improves the metabolic picture further. Adding glucagon (retatrutide) appears to target the liver directly. Each step adds a layer of hepatic benefit, though the diminishing return between 8 mg and 12 mg in the Sanyal trial suggests there may be a ceiling to how much liver fat reduction any single drug can achieve.
A direct comparison of semaglutide, tirzepatide, and retatrutide requires phase 3 data with matched endpoints, which does not yet exist.
For a broader look at cardiovascular outcomes with incretin drugs, see GLP-1 drugs and heart disease.
The Weight Loss Connection
Liver fat and body weight are deeply linked, but retatrutide's liver effects appear to go beyond what weight loss alone explains.
In the parent phase 2 obesity trial published in the NEJM, retatrutide 12 mg produced 24.2% weight loss at 48 weeks in adults with obesity.[11] A systematic review and meta-analysis of 878 patients across three randomized controlled trials confirmed a mean weight reduction of 14.33% across doses, along with significant improvements in BMI, waist circumference, fasting glucose, HbA1c, and blood pressure.[12]
Phase 3 results from TRIUMPH-4 showed 28.7% weight loss at 68 weeks in participants with obesity and knee osteoarthritis, confirming that the weight loss signal holds in larger populations and longer durations. These numbers approach what bariatric surgery achieves.
But here is the key observation from the Sanyal substudy: liver fat reductions were "related to changes in body weight, abdominal fat, and metabolic measures" with statistical confidence, yet the magnitude of liver fat clearance (82-93% achieving normal levels) is disproportionately large relative to the percentage of body weight lost. This suggests the glucagon receptor component is contributing liver-specific fat reduction on top of the weight-mediated effect.[1]
For complete trial results across all endpoints, see retatrutide clinical trial results: up to 24% weight loss.
Beyond Liver Fat: Kidney, Metabolic, and Systemic Effects
Retatrutide's effects extend beyond the liver. A post hoc analysis of kidney parameters found that retatrutide 12 mg reduced the urine albumin-to-creatinine ratio (UACR) by 37% in participants with type 2 diabetes and by 31.5% in participants with obesity at 48 weeks.[14] In the obesity cohort, eGFR actually increased by 8.5 mL/min/1.73 m2 at the 12 mg dose. These kidney findings are relevant because MASLD and chronic kidney disease share metabolic drivers, and kidney disease is a common comorbidity.
The preclinical comparison by Ma et al. (2025) found that retatrutide outperformed both liraglutide and tirzepatide at reducing renal inflammation markers (TNF-alpha, caspase-1, NLRP3) and fibrosis markers (fibronectin, alpha-SMA, collagen I) in diabetic mice, while also improving liver function and lipid profiles.[7] These findings support the idea that triple agonism provides systemic metabolic benefits that extend across organ systems.
The cardiovascular picture is more nuanced. Retatrutide increased heart rate by up to 6.7 beats per minute in phase 2 trials, consistent with GLP-1 receptor agonism.[11] Whether this is clinically meaningful over the long term, especially in a population that typically carries elevated cardiovascular risk, remains an open question that phase 3 cardiovascular outcome trials will need to answer.[4]
Other peptide-based compounds also target liver protection through different mechanisms. BPC-157 and liver protection reviews the animal data on a body protection compound that appears to mitigate liver damage in rodent models, though through an entirely different pathway than incretin-based therapies.
Phase 3: The TRIUMPH Program and What Comes Next
Eli Lilly's phase 3 TRIUMPH program encompasses more than 5,800 participants across multiple trials evaluating retatrutide at doses of 4 mg, 9 mg, and 12 mg. The program includes trials in:
- Obesity and overweight with weight-related comorbidities
- Type 2 diabetes
- Knee osteoarthritis (TRIUMPH-4, reported December 2025)
- Obstructive sleep apnea
- Chronic low back pain
- Cardiovascular and renal outcomes
- Metabolic dysfunction-associated steatotic liver disease (MASLD-specific trial)
TRIUMPH-4 was the first phase 3 trial to report results, showing 28.7% mean weight loss at 68 weeks in 445 participants with obesity and knee osteoarthritis, alongside substantial pain relief. Additional TRIUMPH results are expected throughout 2026.
The MASLD-specific phase 3 trial is particularly important because it should include liver biopsy endpoints, measuring actual MASH resolution and fibrosis improvement rather than just imaging-based fat content. This will determine whether retatrutide's dramatic liver fat reduction translates into histological disease modification. A post hoc analysis of the SYNERGY-NASH data already showed consistent improvements in liver histology across subgroups including age, sex, BMI, diabetes status, and fibrosis stage, providing indirect support for the hypothesis that multi-receptor agonism benefits the liver broadly.[15]
For timeline details, see when will retatrutide be available? FDA timeline and what to expect.
Limitations and Open Questions
The evidence for retatrutide's liver effects, while striking, comes with significant caveats.
Small sample size. The MASLD substudy included only 98 participants. Phase 3 data in thousands of participants is needed to confirm the magnitude and durability of the effect.
No liver biopsies. MRI-PDFF measures liver fat content but cannot assess inflammation, hepatocyte injury, or fibrosis. Reducing liver fat is meaningful, but what matters clinically is whether retatrutide prevents or reverses the progression from simple steatosis to MASH to fibrosis to cirrhosis.
Homogeneous population. The trial enrolled predominantly white participants in the United States and excluded people with type 2 diabetes. MASLD prevalence and progression vary substantially by ethnicity and metabolic profile. Generalizability is uncertain.
Missing data. MRI data at 48 weeks was missing for 56.1% of participants. The impressive 93% resolution rate is based on available completers and may overestimate the effect in an intention-to-treat analysis.
No active comparator. The trial compared retatrutide to placebo, not to semaglutide, tirzepatide, or resmetirom. Head-to-head comparisons are the only way to determine retatrutide's relative advantage.
Long-term safety unknown. Glucagon receptor activation raises theoretical concerns about blood glucose elevation and potential cardiovascular effects. The heart rate increase of up to 6.7 bpm, while mild, needs monitoring over years of treatment.[11]
Durability unclear. What happens to liver fat if retatrutide is discontinued? Weight regain after stopping GLP-1 drugs is well-documented. Whether liver fat reaccumulates at the same rate as body fat is unknown.
These are not reasons to dismiss the data. They are reasons to wait for phase 3 results before drawing conclusions about retatrutide's role in MASLD treatment.
The Bigger Picture: Why Triple Agonism Matters for Liver Disease
The progression from single-target GLP-1 drugs to dual GLP-1/GIP agonists to triple GLP-1/GIP/glucagon agonists represents a deliberate escalation in metabolic drug design.[2] Each additional receptor target has incrementally improved weight loss outcomes: semaglutide achieves roughly 15%, tirzepatide reaches about 21%, and retatrutide has now shown up to 28.7% in phase 3.
But for liver disease specifically, the glucagon receptor may matter more than the incremental weight loss. Glucagon's direct action on hepatocytes, stimulating beta-oxidation and suppressing new fat production, addresses the root pathology of MASLD at the organ level rather than relying entirely on systemic metabolic improvement.[6]
This has implications beyond retatrutide. Other glucagon-inclusive agonists in development, including cotadutide (a dual GLP-1/glucagon agonist), efinopegdutide, and mazdutide, all leverage this hepatic mechanism. The survodutide phase 2 data reinforces the principle: glucagon receptor activation drives liver-specific outcomes that exceed what GLP-1 alone achieves.[13] The liver may be where the glucagon component proves most clinically valuable, even more so than in weight loss.
Meanwhile, the liver itself produces metabolic hormones that interact with these pathways. FGF21, a hepatokine involved in lipid metabolism and insulin sensitivity, represents another therapeutic target in the same disease space.
The Bottom Line
Retatrutide's phase 2a data shows the largest liver fat reductions reported for any incretin-based therapy, with up to 93% of participants achieving normal liver fat levels at 48 weeks. The glucagon receptor component appears to drive liver-specific benefits beyond what weight loss alone achieves. Phase 3 trials with biopsy-confirmed MASH endpoints will determine whether these imaging results translate into histological disease modification and meaningful clinical outcomes.